OCULAR THERAPEUTIX, INC Operating Lease, Liability, Current
OCULAR THERAPEUTIX, INC (OCUL) had Operating Lease, Liability, Current of $3.12 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-08-03
- 2026-06-30: Operating Lease, Liability, Current $3.12M.
- 2026-03-31: Operating Lease, Liability, Current $3.17M.
- 2025-12-31: Operating Lease, Liability, Current $2.82M.
- 2025-09-30: Operating Lease, Liability, Current $2.76M.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2026-06-30 | $3.12M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $3.17M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $2.82M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $2.76M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $2.63M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $2.16M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $1.93M 10-K · filed 2026-02-05 |
| 2024-09-30 | $1.72M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $1.66M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $1.54M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $1.59M 10-K · filed 2025-03-03 |
| 2023-09-30 | $1.88M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $1.71M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $1.82M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $1.60M 10-K · filed 2024-03-11 |
| 2022-09-30 | $1.74M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $1.77M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $1.70M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $1.62M 10-K · filed 2023-03-06 |
| 2021-09-30 | $1.55M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $1.49M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $1.42M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $1.36M 10-K · filed 2022-02-28 |
| 2020-09-30 | $1.30M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $1.24M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $1.18M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $1.13M 10-K · filed 2021-03-11 |
| 2019-09-30 | $1.07M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $1.02M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $675.00K 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |